Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The intravenous medication, which should be used with standard antiretrovirals, has a wholesale acquisition cost of $118,000 per year.
With an FDA decision for ibalizumab pending, data about a group with multidrug resistance show that the antibody is effective.
TaiMed Biologics has applied for approval of the weekly injectable antibody ibalizumab for people with multidrug-resistant virus.
TaiMed Biologics has applied for approval of the weekly injectable antibody ibalizumab for those with multidrug-resistant virus.
A look at the most notable HIV-related studies presented at the 2017 Conference on Retroviruses and Opportunistic Infections in Seattle.
The injectable long-acting antibody against HIV ibalizumab has shown promise in a trial of people with virus that’s resistant to multiple...
In a Phase III trial, participants responded well to the addition of biweekly injections of the cloned antibody ibalizumab.
“We need drugs that are gentler, kinder, better and cheaper.”
Long-awaited results from a Phase II study of ibalizumab, an antibody-based therapy in early stage development for several years
Ironically, the success of today’s antiretroviral treatments has hindered the development of new options for longtime survivors with drug...
Experts think we’re about to enter a dry spell in terms of new HIV treatments, with no truly novel compounds available for treatment...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.